CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
doxycycline monohydrate +1 moredrug
Likely dose
doxycycline monohydrate 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00917553
NCT00917553Phase 2Completed
CompareCT.gov

Proof-of-Concept 2 (POC2): Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy Progression in Patients With Mild to Moderate Non-Proliferative Diabetic Retinopathy

Thomas Gardner·interventional·Posted Jun 10, 2009·Updated Nov 30, 2018

In Brief

A Phase 2 clinical trial evaluating doxycycline monohydrate and Placebo for Diabetic Retinopathy. Completed, enrolled 33 participants across 1 site.

Detailed Summary

This 24 month randomized research study will evaluate whether doxycycline can slow the deterioration or improve retinal function among patients with mild to moderate non-proliferative diabetic retinopathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Retinopathy
CountriesUnited States
CollaboratorsPenn State University, Juvenile Diabetes Research Foundation

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 10, 2009
Enrollment StartJul 1, 2009
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 17.1 years ago

Interventions

doxycycline monohydratedrug

50 mg

Placebodrug

Cellulose Placebo Capsule